 5. Subjects with a life-threatening illness, medical condition or organ system dysfunction, or other reasons which, in the Investigators opinion, could compromise the subjects safety, interfere with or compromise the integrity of the study outcomes including incomplete recovery from the acute effects from any prior anti-neoplastic therapy. 